NASDAQ · KPTI
Healthcare · Biotechnology
$1.69
Down-$0.07 (-4.14%)
Updated Sep 10, 2026, 10:05 PM
SID Score
3.0/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
KPTI closed at $1.69 after 20 trading sessions, down 16.75% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 9, 2026 | $1.72 | $1.75 | $1.65 | $1.69 | 772.57K |
| Sep 8, 2026 | $1.77 | $1.79 | $1.70 | $1.72 | 1.01M |
| Sep 4, 2026 | $1.77 | $1.84 | $1.755 | $1.79 | 577.79K |
| Sep 3, 2026 | $1.79 | $1.8062 | $1.72 | $1.77 | 819.68K |
| Sep 2, 2026 | $1.90 | $1.94 | $1.725 | $1.79 | 1.3M |
| Sep 1, 2026 | $2.02 | $2.065 | $1.84 | $1.85 | 1.6M |
| Aug 31, 2026 | $1.91 | $2.14 | $1.7907 | $2.06 | 2.03M |
| Aug 28, 2026 | $1.98 | $1.99 | $1.86 | $1.87 | 827.35K |
| Aug 27, 2026 | $1.99 | $2.06 | $1.9301 | $1.94 | 1.11M |
| Aug 26, 2026 | $1.92 | $1.99 | $1.86 | $1.96 | 753.81K |
| Aug 25, 2026 | $1.87 | $1.95 | $1.87 | $1.92 | 1.06M |
| Aug 24, 2026 | $1.95 | $1.96 | $1.83 | $1.86 | 845.77K |
| Aug 21, 2026 | $1.85 | $1.97 | $1.822 | $1.96 | 876.79K |
| Aug 20, 2026 | $2.00 | $2.00 | $1.82 | $1.82 | 865.65K |
| Aug 19, 2026 | $1.93 | $2.0153 | $1.93 | $2.00 | 792.13K |
| Aug 18, 2026 | $1.88 | $1.96 | $1.82 | $1.93 | 1.15M |
| Aug 17, 2026 | $2.02 | $2.03 | $1.79 | $1.81 | 1.39M |
| Aug 14, 2026 | $1.97 | $2.06 | $1.97 | $2.02 | 886.92K |
| Aug 13, 2026 | $2.03 | $2.0865 | $1.92 | $1.99 | 1.73M |
| Aug 12, 2026 | $2.10 | $2.1491 | $2.00 | $2.03 | 1.84M |
The latest Smart Investors Daily articles mentioning KPTI.
KPTI research
Company profile and research snapshot.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 31, 2026 | Piper Sandler | Overweight | — |
| Jul 31, 2026 | HC Wainwright & Co. | Neutral | — |
| May 6, 2026 | HC Wainwright & Co. | Buy | — |
| Apr 27, 2026 | Piper Sandler | Overweight | — |
| Mar 30, 2026 | Piper Sandler | Overweight | — |
No generated briefing is available yet.
Benzinga · Aug 31, 2026
– sNDA Submitted under the Accelerated Approval Pathway; Priority Review Requested –NEWTON, Mass., Aug. 31, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company
SeekingAlpha · Aug 18, 2026
Genron Corp. reported Q2'26 net product revenues of $57.5M from U.S. sales of Rytelo, up 11% from Q1'26. Learn why GERN stock is a buy.
Yahoo · Aug 14, 2026
Moby summary of Karyopharm Therapeutics Inc.'s Q2 2026 earnings call
Yahoo · Aug 13, 2026
Karyopharm reports promising myelofibrosis data and plans for accelerated approval sNDA, while navigating a tight cash position and failed endometrial cancer program.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning KPTI.
